Abstract | OBJECTIVE: DESIGN AND METHODS: RESULTS: CONCLUSIONS:
Octreotide is an effective treatment of hypoglycaemia in more than 50% of patients with insulinoma. Detection of responsive patients was better based on a positive short test with subcutaneous octreotide than on the results of Octreoscan scintigraphy. Positive anti-sst2 receptor immunostaining is associated with efficacy of octreotide treatment, but does not account for all cases of responsiveness to octreotide. Expression of sst5 receptor does not appear to explain per se the efficacy of octreotide on sst2A-negative insulinomas.
|
Authors | Delphine Vezzosi, Antoine Bennet, Philippe Rochaix, Frédéric Courbon, Jannick Selves, Bernard Pradere, Louis Buscail, Christiane Susini, Philippe Caron |
Journal | European journal of endocrinology
(Eur J Endocrinol)
Vol. 152
Issue 5
Pg. 757-67
(May 2005)
ISSN: 0804-4643 [Print] England |
PMID | 15879362
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Blood Glucose
- Indium Radioisotopes
- Receptors, Somatostatin
- somatostatin receptor sst2A
- Somatostatin
- somatostatin receptor 5
- pentetreotide
- Octreotide
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Blood Glucose
(drug effects)
- Female
- Humans
- Hypoglycemia
(drug therapy, metabolism)
- Immunohistochemistry
- Indium Radioisotopes
- Insulinoma
(diagnostic imaging, drug therapy, metabolism)
- Male
- Middle Aged
- Octreotide
(administration & dosage)
- Pancreatic Neoplasms
(diagnostic imaging, drug therapy, metabolism)
- Radionuclide Imaging
- Receptors, Somatostatin
(metabolism)
- Somatostatin
(analogs & derivatives)
|